The role of albumin–bilirubin grade and inflammation-based index in patients with hepatocellular carcinoma treated with stereotactic body radiotherapy

[1]  P. Schirmacher,et al.  EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. , 2018, Journal of hepatology.

[2]  H. Pitt,et al.  Albumin-Bilirubin Score: Predicting Short-Term Outcomes Including Bile Leak and Post-hepatectomy Liver Failure Following Hepatic Resection , 2017, Journal of Gastrointestinal Surgery.

[3]  D. Baltas,et al.  Stereotactic body radiotherapy (SBRT) in recurrent or oligometastatic pancreatic cancer , 2017, Strahlentherapie und Onkologie.

[4]  D. Baltas,et al.  Simultaneous integrated protection , 2016, Strahlentherapie und Onkologie.

[5]  R. Man,et al.  Stereotactic body radiation therapy for primary and metastatic liver tumors: From technological evolution to improved patient care. , 2016 .

[6]  M. Abecassis,et al.  Independent Analysis of Albumin-Bilirubin Grade in a 765-Patient Cohort Treated with Transarterial Locoregional Therapy for Hepatocellular Carcinoma. , 2016, Journal of vascular and interventional radiology : JVIR.

[7]  B. Sangro,et al.  Long-term impact of liver function on curative therapy for hepatocellular carcinoma: application of the ALBI grade , 2016, British Journal of Cancer.

[8]  L. Dawson,et al.  Predictors of Liver Toxicity Following Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma. , 2015, International journal of radiation oncology, biology, physics.

[9]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[10]  B. Sangro,et al.  Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  M. Kudo,et al.  Dynamic changes of the inflammation‐based index predict mortality following chemoembolisation for hepatocellular carcinoma: a prospective study , 2014, Alimentary pharmacology & therapeutics.

[12]  L. Dawson,et al.  Outcomes following definitive stereotactic body radiotherapy for patients with Child-Pugh B or C hepatocellular carcinoma. , 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[13]  G. Gores,et al.  Hepatocellular carcinoma: clinical frontiers and perspectives , 2014, Gut.

[14]  H. Heinzl,et al.  The ART of decision making: Retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma , 2013, Hepatology.

[15]  Zahra Kassam,et al.  Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Shahid A. Khan,et al.  A novel and validated prognostic index in hepatocellular carcinoma: the inflammation based index (IBI). , 2012, Journal of hepatology.

[17]  Rohini Sharma,et al.  An inflammation-based prognostic index predicts survival advantage after transarterial chemoembolization in hepatocellular carcinoma. , 2012, Translational research : the journal of laboratory and clinical medicine.

[18]  Clara Alsinet,et al.  Gene signatures in the management of hepatocellular carcinoma. , 2012, Seminars in oncology.

[19]  J. Bruix,et al.  Management of hepatocellular carcinoma: An update , 2011, Hepatology.

[20]  M. Miften,et al.  Radiation-associated liver injury. , 2010, International journal of radiation oncology, biology, physics.

[21]  M. Okada,et al.  [New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1)]. , 2009, Gan to kagaku ryoho. Cancer & chemotherapy.

[22]  Robert D Timmerman,et al.  An overview of hypofractionation and introduction to this issue of seminars in radiation oncology. , 2008, Seminars in radiation oncology.

[23]  P. Allavena,et al.  Cancer-related inflammation , 2008, Nature.

[24]  Xin Wei Wang,et al.  Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. , 2006, Cancer cell.

[25]  John D Fenwick,et al.  A challenge to traditional radiation oncology. , 2004, International journal of radiation oncology, biology, physics.

[26]  R. Groszmann,et al.  American association for the study of liver diseases , 1992 .

[27]  R. Pugh,et al.  Transection of the oesophagus for bleeding oesophageal varices , 1973, The British journal of surgery.

[28]  M. Kudo,et al.  The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma. , 2017, Journal of hepatology.

[29]  Riccardo Lencioni,et al.  EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. , 2012, Journal of hepatology.

[30]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.